PremiumCompany AnnouncementsAltimmune’s 2025 Q1 Results Highlight Clinical Progress Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension Altimmune secures up to $100M in credit facility PremiumThe FlyAltimmune management to meet with Piper Sandler Altimmune’s Pemvidutide: A Promising Catalyst with Blockbuster Potential and Strong Financial Backing Altimmune’s Strategic Positioning and Promising Future in Obesity and MASH Treatment Markets PremiumThe FlyAltimmune call volume above normal and directionally bullish Evercore bullish on Altimmune, likes drug move into alcohol related disease Promising Potential of Altimmune’s Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook 
